Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
14.99
+0.02 (0.13%)
At close: Dec 24, 2024, 1:00 PM
14.87
-0.12 (-0.80%)
After-hours: Dec 24, 2024, 2:50 PM EST
Arcutis Biotherapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for ARQT stock have an average target of 15.5, with a low estimate of 11 and a high estimate of 18. The average target predicts an increase of 3.40% from the current stock price of 14.99.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 7, 2024.
Analyst Ratings
The average analyst rating for ARQT stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 1 | 1 | 1 | 1 | 0 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 6 | 6 | 6 | 6 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +20.08% | Nov 7, 2024 |
| Jefferies | Jefferies | Strong Buy Initiates $15 | Strong Buy | Initiates | $15 | +0.07% | Aug 28, 2024 |
| Needham | Needham | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +20.08% | Aug 15, 2024 |
| Needham | Needham | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +20.08% | Jul 30, 2024 |
| Needham | Needham | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +20.08% | Jul 10, 2024 |
Financial Forecast
Revenue This Year
183.78M
from 59.61M
Increased by 208.32%
Revenue Next Year
273.03M
from 183.78M
Increased by 48.56%
EPS This Year
-1.38
from -3.78
EPS Next Year
-1.00
from -1.38
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 192.9M | 313.6M | 498.8M | |||
| Avg | 183.8M | 273.0M | 416.9M | |||
| Low | 173.8M | 217.5M | 274.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 223.6% | 70.7% | 82.7% | |||
| Avg | 208.3% | 48.6% | 52.7% | |||
| Low | 191.5% | 18.3% | 0.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.30 | -0.82 | 0.42 | |||
| Avg | -1.38 | -1.00 | -0.04 | |||
| Low | -1.40 | -1.15 | -0.48 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.